

## **LIST OF FIGURES**

<b>Part I : Potential NMDA Receptor Antagonist</b>		<b>Page No</b>
Fig.	Progressive illustrations of brain degeneration caused by	05
1.1	Alzheimer's disease.	
Fig.	Therapeutic targets for Alzheimer's disease,	06
1.2		
Fig.	Schematic illustration of apoptotic pathways triggered by excessive	14
1.3	NMDA receptor activity.	
Fig.	NMDA receptor model illustrating important binding and	15
1.4	modulatory sites.	
Fig.	Development of 3-benzazepins as NMDA receptor antagonists.	32
3.1		
Fig.	SAR of benzazepines for NMDA receptor glycine site antagonistic	33
3.2	activity	
Fig.	Designed benzazepine-2-ones with substituents at 1 and 3 position	33
3.3		
Fig.	<i>In vitro</i> neuroprotective potential of the test compounds ( <b>9</b> and <b>14</b> )	67
4.1	against A $\beta$ <sub>1-42</sub> -induced toxicity.	
Fig.	Morris water maze test	68
4.2		
Fig.	<i>in vitro</i> ROS scavenging and antiapoptotic effects	69
4.3		
<b>Part II : Novel Cholinesterase Inhibitors</b>		<b>Page No</b>
Fig.	Changes in Alzheimer's brain	02
1.1		
Fig.1.2	FDA approved anticholinesterase drugs for Alzheimer's disease	03
Fig.	2,3-Substituted Quinazolinones as CNS acting agents	24
3.1		
Fig.	Compounds with good anticholinesterase activity	25
3.2		
Fig.	Test compound ( <b>75</b> ) enhanced spatial learning ability of	46
4.1	scopolamine-induced amnesic mice in MWM test.	
Fig.	Test compound ( <b>75</b> ) restored immediate working memory	47
4.2	impairment induced by ICV injection of A $\beta$ <sub>1-42</sub> in hippocampal	
	region of rat brains as observed in Y maze test.	
Fig.	<i>In vitro</i> ROS scavenging and antiapoptotic effects of test compound	48
4.3	( <b>75</b> ) against A $\beta$ <sub>1-42</sub> -induced toxicity of hippocampal neurons.	